Schizophrenia (SCZ) is a profoundly disabling neurodevelopmental disorder causing marked functional impairment. SCZ is hypothesized to arise from synaptic disturbances affecting large-scale neural connectivity along cortico?thalamic- striatal?cortical (CTSC) pathways. Neuroimaging evidence supports this view by showing alterations in associative cortices and connectivity disruptions across CTSC circuits in chronic SCZ. Yet, the complex evolving neurobiology of early-course SCZ remains uncharacterized. This limits treatments for early illness phases when intervention is crucial by capitalizing on the narrow `window' of opportunity to halt disease progression. Thus, understanding the neurobiology of early-course SCZ is a major objective for early detection, prognosis prediction and targeted individualized therapy. A major complicating factor in many SCZ studies is the confounding presence of antipsychotic treatment. Thus, our goal is to characterize co-occurring functional and structural dysconnectivity in unmedicated early-course SCZ and quantify neural changes in relation to cardinal SCZ symptoms, cognitive deficits and treatment response. To achieve this, we will examine longitudinal progression of neural dysconnectivity in 150 unmedicated early-course SCZ patients after their initial admission into clinics affiliated with West China Hospital. We will follow patients longitudinally at 6, 12, and 24 months later in comparison with 150 matched healthy controls. We will use state-of-the-art functional and structural methods optimized by the Human Connectome Project to achieve cutting-edge multi-modal neuroimaging integration. As noted, mounting evidence implicates CTSC loops in SCZ, particularly higher-order prefrontal and thalamic regions (e.g. medio-dorsal structures), suggesting mechanistic links between CTSC dysfunction and SCZ symptoms. Thus, first we aim to test if the identified CTSC markers exhibit concurrent (or dissociable) structural and functional alterations in unmedicated SCZ patients and if these circuits alter longitudinally. Second, we will test if structural and functional neuroimaging alterations relate to severity of cardinal SCZ symptoms and cognitive deficits. This provides a much-needed mapping between longitudinal CTSC dysconnectivity, symptoms and cognition in SCZ. Critically, this balanced longitudinal design can distinguish `state' versus `trait' neuroimaging markers during early illness course in relation to clinically relevant variables. Finally, it is well established that many SCZ patients do not respond well to antipsychotics. Yet, the neural markers of poor treatment response remain unmapped (and conversely treatment response). A key advantage of the proposed U.S.-China partnership is precisely the capacity to longitudinally study large sample sizes starting from medication-free observations, afforded by extensive and robust recruitment infrastructure at West China Hospital. Thus, our third aim is to quantify longitudinal structural and functional CTSC dysconnectivity in relation to treatment response. Collectively, this study will map longitudinal `state' versus `trait' neural markers starting from medication-free early illness stages (Aim 1), relate these changes to symptom dynamics (Aim 2) and treatment response (Aim 3). This mapping is vital to inform future work aimed at maximizing individualized early intervention strategies.

Public Health Relevance

There are critical knowledge gaps in understanding time-dependent neural change in unmedicated early-course schizophrenia, especially in relation to progressive symptom dynamics and treatment response, which is vital to minimize duration of untreated psychosis and capitalize on the narrow `window' of opportunity for early intervention. This large- scale collaborative clinical study between the U.S. and China aims to examine concurrent multi-modal functional and structural dysconnectivity along cortico?thalamic-striatal?cortical loops in unmedicated early-course schizophrenia, and quantify longitudinal neural changes in relation to symptoms, cognition and treatment response patterns via cutting-edge brain imaging. In doing so, this proposal aims to map longitudinal neural targets of early-course schizophrenia progression in relation to clinically applicable variables, namely symptom dynamics and treatment response, ultimately providing novel neurobiologically-grounded targets for guiding individualized early intervention strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH112189-02
Application #
9418116
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Rumsey, Judith M
Project Start
2017-02-01
Project End
2021-11-30
Budget Start
2017-12-08
Budget End
2018-11-30
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520